Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...
Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -- ...
As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) ...
Theriva Biologics announced the completion of patient enrollment in its Phase 2b clinical trial called VIRAGE, which evaluates VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC), with ...
Merck & Co. Inc. (NYSE:MRK) is one of the most promising stocks under $100. On October 6, Merck & Co. announced the initiation of three new Phase 2b trials for tulisokibart (MK-7240). Tulisokibart is ...
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema Phase IIb trial to ...
In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...
Clinical Trials Arena on MSN
J&J’s Imaavy posts win in Phase II SLE trial
Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback